LONDON, May 3, 2024 – A $1.3 billion deal that promised to reshape the pharmaceutical manufacturing landscape is hitting a potential roadblock, not because of financial hurdles, but due to concerns raised by the UK’s Competition and Markets Authority (CMA).The regulator is scrutinizing the proposed merger between Catalent and Sterling Pharma Solutions, fearing it could lead to a duopoly in the supply of a critical Active Pharmaceutical Ingredient (API).
What exactly is the CMA worried about? The competition regulator believes the combined entity would control a meaningful share of the market for a particular API-a crucial component in numerous medications-leaving only one other major supplier. This limited competition, the CMA argues, could empower the merged company to dictate prices and perhaps compromise the security of the drug supply chain.
The API at the Heart of the Matter
The specific API in question hasn’t been publicly named, but its importance to a range of pharmaceutical products is undeniable. The CMA’s concern isn’t simply about market share; its about the potential for the merged company to exploit its dominant position.
The CMA launched its Phase 2 investigation on April 18, 2024, signaling a deeper dive into the potential consequences of the merger. Both Catalent and Sterling Pharma Solutions have been cooperating with the investigation, submitting detailed information about their operations and the competitive landscape.
The regulator is now expected to deliver its final decision by June 13, 2024. If the CMA concludes that the merger would substantially lessen competition, it could block the deal outright or impose conditions designed to mitigate the concerns.These conditions might include requiring the merged company to divest certain assets or agree to supply contracts with competitors.
What’s Next for Catalent and Sterling?
The outcome of the CMA’s investigation will have significant implications for both companies and the broader pharmaceutical industry. A blocked merger would force both parties to reassess their strategies, while conditions imposed by
